BNP/CALL/MODERNA/220/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 03:50:41 2024-05-27 pm EDT | ||
| 1.26 EUR | 0.00% |
|
| Current month | +563.16% | ||
| 1 month | +641.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 1.26 | 0.00% |
| 24-05-24 | 1.26 | +6.78% |
| 24-05-23 | 1.18 | +3.51% |
| 24-05-22 | 1.14 | +115.09% |
| 24-05-21 | 0.53 | +6.00% |
Delayed Quote Deutsche Boerse AG
Last update May 27, 2024 at 03:50 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE89C5 |
| ISIN | DE000PE89C58 |
| Date issued | 2023-02-16 |
| Strike | 220 $ |
| Maturity | 2024-12-20 (207 Days) |
| Parity | 10 : 1 |
| Emission price | 3.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.93 € |
|---|---|
| Lowest since issue | 0.085 € |
| Spread | 0.02 € |
| Spread % | 1.55% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- Warrant
